CIK 0001689375 · Accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813983399
- Phone
- 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-29 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −1,000 | $19.97 | $20K | 73,849 |
| 2024-11-29 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,000 | 36,157 | ||
| 2024-11-29 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −100 | $20.00 | $2K | 160,788 |
| 2024-11-13 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −2,700 | $20.04 | $54K | 160,888 |
| 2024-11-11 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −1,409 | $20.01 | $28K | 163,588 |
| 2024-11-11 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +6,000 | $2.10 | $13K | 82,486 |
| 2024-11-11 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −8,637 | $19.98 | $173K | 73,849 |
| 2024-11-11 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 37,157 | ||
| 2024-11-06 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −9,554 | $18.71 | $179K | 167,742 |
| 2024-11-06 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −2,745 | $19.32 | $53K | 164,997 |
| 2024-11-05 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −5,171 | $18.18 | $94K | 177,296 |
| 2024-11-04 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −749 | $18.02 | $13K | 182,467 |
| 2024-10-16 | Sethuraman Natarajan President, Research & Develop. | Sale 10b5-1 | −600 | $18.00 | $11K | 183,216 |
| 2024-09-26 | Dowden Nathan J President & COO | Sale 10b5-1 | −847 | $16.00 | $14K | 125,149 |
| 2024-09-09 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −3,195 | $14.97 | $48K | 76,486 |
| 2024-09-09 | Dowden Nathan J President & COO | Sale 10b5-1 | −1,904 | $15.07 | $29K | 125,996 |
| 2024-09-09 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −2,642 | $15.09 | $40K | 183,816 |
| 2024-09-06 | Dowden Nathan J President & COO | Sale 10b5-1 | −399 | $15.19 | $6K | 127,900 |
| 2024-09-06 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −600 | $15.24 | $9K | 186,458 |
| 2024-09-05 | Doshi Dipal CEO | Shares withheld for taxes | −826 | $15.13 | $12K | 325,753 |
Page 8 of 12 · 230 trades